Nothing Special   »   [go: up one dir, main page]

SMT202400144T1 - Forme cristalline di un inibitore di fosfoinositide 3-chinasi (pi3k) - Google Patents

Forme cristalline di un inibitore di fosfoinositide 3-chinasi (pi3k)

Info

Publication number
SMT202400144T1
SMT202400144T1 SM20240144T SMT202400144T SMT202400144T1 SM T202400144 T1 SMT202400144 T1 SM T202400144T1 SM 20240144 T SM20240144 T SM 20240144T SM T202400144 T SMT202400144 T SM T202400144T SM T202400144 T1 SMT202400144 T1 SM T202400144T1
Authority
SM
San Marino
Prior art keywords
phosphoinositide
pi3k
kinase
inhibitor
crystalline forms
Prior art date
Application number
SM20240144T
Other languages
English (en)
Inventor
Brent Douty
Zhongjiang Jia
Andrew P Combs
Eddy W Yue
David M Burns
Daniel Levy
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SMT202400144T1 publication Critical patent/SMT202400144T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SM20240144T 2018-09-05 2019-09-04 Forme cristalline di un inibitore di fosfoinositide 3-chinasi (pi3k) SMT202400144T1 (it)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862727328P 2018-09-05 2018-09-05
US201862727321P 2018-09-05 2018-09-05
US201862727339P 2018-09-05 2018-09-05
US201862746928P 2018-10-17 2018-10-17
EP19858443.5A EP3847175B1 (en) 2018-09-05 2019-09-04 Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
PCT/US2019/049419 WO2020051169A1 (en) 2018-09-05 2019-09-04 Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor

Publications (1)

Publication Number Publication Date
SMT202400144T1 true SMT202400144T1 (it) 2024-05-14

Family

ID=69642051

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20240144T SMT202400144T1 (it) 2018-09-05 2019-09-04 Forme cristalline di un inibitore di fosfoinositide 3-chinasi (pi3k)

Country Status (32)

Country Link
US (2) US11186580B2 (it)
EP (2) EP4338801A3 (it)
JP (1) JP7592006B2 (it)
KR (1) KR20210091121A (it)
CN (1) CN113677683B (it)
AU (2) AU2019336675B2 (it)
BR (1) BR112021004094A2 (it)
CA (1) CA3111629A1 (it)
CL (1) CL2021000539A1 (it)
CO (1) CO2021004061A2 (it)
CR (1) CR20210165A (it)
DK (1) DK3847175T3 (it)
EC (1) ECSP21022719A (it)
ES (1) ES2976576T3 (it)
FI (1) FI3847175T3 (it)
HR (1) HRP20240252T1 (it)
HU (1) HUE066111T2 (it)
IL (2) IL309869A (it)
LT (1) LT3847175T (it)
MA (1) MA53561A (it)
MD (1) MD3847175T2 (it)
MX (2) MX2021002551A (it)
PE (1) PE20211815A1 (it)
PH (1) PH12021550472A1 (it)
PL (1) PL3847175T3 (it)
PT (1) PT3847175T (it)
RS (1) RS65334B1 (it)
SG (1) SG11202102224UA (it)
SI (1) SI3847175T1 (it)
SM (1) SMT202400144T1 (it)
TW (2) TWI833796B (it)
WO (1) WO2020051169A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738057B2 (en) * 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
WO2020051169A1 (en) 2018-09-05 2020-03-12 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
AU2002215608B2 (en) 2000-06-28 2004-12-09 Smithkline Beecham P.L.C. Wet milling process
CN100391958C (zh) 2001-09-19 2008-06-04 安万特医药股份有限公司 化合物
CA2465247C (en) 2001-10-26 2010-05-18 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
ES2269793T3 (es) 2001-10-30 2007-04-01 Novartis Ag Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3.
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004078943A2 (en) 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
TW200530238A (en) 2003-10-15 2005-09-16 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
WO2005123719A1 (en) 2004-06-10 2005-12-29 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2008520612A (ja) 2004-11-24 2008-06-19 ノバルティス アクチエンゲゼルシャフト ＪＡＫ阻害剤およびＢｃｒ−Ａｂｌ、Ｆｌｔ−３、ＦＡＫまたはＲＡＦキナーゼ阻害剤のうち少なくとも１個の組合せ
JP5203196B2 (ja) 2005-08-04 2013-06-05 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのオキサゾロピリジン誘導体
TW200800213A (en) * 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
CA2681813A1 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
AU2008321046B2 (en) 2007-11-16 2013-10-24 Incyte Holdings Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
US20110052562A1 (en) 2007-12-19 2011-03-03 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
AU2009232276B2 (en) 2008-01-15 2013-10-24 Kineta Four Llc Antiviral drugs for treatment of arenavirus infection
EP2257161B1 (en) 2008-02-26 2012-04-25 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
WO2009114512A1 (en) 2008-03-11 2009-09-17 Incyte Corporation Azetidine and cyclobutane derivatives as jak inhibitors
WO2009133127A1 (en) 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
CA2763536C (en) 2008-05-30 2017-05-09 Marvin J. Miller Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
WO2010051245A1 (en) 2008-11-03 2010-05-06 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
TW201028399A (en) 2008-11-27 2010-08-01 Shionogi & Co Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
EP2401273A1 (en) 2009-02-27 2012-01-04 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
BRPI1014572B8 (pt) 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SI2448938T1 (sl) 2009-06-29 2014-08-29 Incyte Corporation Experimental Station Pirimidinoni kot zaviralci pi3k
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011075630A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
WO2011112662A1 (en) 2010-03-10 2011-09-15 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
JP2013523766A (ja) 2010-03-31 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのイミダゾリル‐イミダゾール
US9193721B2 (en) 2010-04-14 2015-11-24 Incyte Holdings Corporation Fused derivatives as PI3Kδ inhibitors
US8877707B2 (en) 2010-05-24 2014-11-04 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
US8623857B2 (en) 2010-05-26 2014-01-07 Merck Sharp & Dohme Corp. N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
CN103237450A (zh) 2010-10-13 2013-08-07 米伦纽姆医药公司 杂芳基化合物和其用途
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
US8729102B2 (en) 2010-11-30 2014-05-20 Takeda Pharmaceutical Company Limited Bicyclic compound
US9096600B2 (en) 2010-12-20 2015-08-04 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
KR20140093610A (ko) 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
JP6463631B2 (ja) 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Ｇｐｒ−１１９のモジュレータとしての新規化合物
MX344479B (es) 2011-06-20 2016-12-16 Incyte Holdings Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de cinasa janus (jak).
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
PH12021552978A1 (en) 2011-09-02 2022-08-22 Incyte Holdings Corp Heterocyclylamines as pi3k inhibitors
CN104066735B (zh) * 2012-01-10 2016-08-31 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的咪唑并吡嗪
JP5854390B2 (ja) 2012-03-01 2016-02-09 学校法人兵庫医科大学 新規ベンズイミダゾール誘導体及びその用途
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR091079A1 (es) 2012-05-18 2014-12-30 Incyte Corp Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
JP6217629B2 (ja) 2012-05-31 2017-10-25 住友化学株式会社 縮合複素環化合物
WO2014011900A2 (en) 2012-07-11 2014-01-16 Blueprint Medicines Inhibitors of the fibroblast growth factor receptor
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
EP2976077A4 (en) 2013-03-22 2016-11-30 Scripps Research Inst SUBSTITUTED BENZIMIDAZOLE AS NOCICEPTIN RECEPTOR MODULATORS
US9394254B2 (en) 2013-05-08 2016-07-19 The University of Denver and Regis University Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase
FI3786162T3 (fi) 2013-05-17 2023-10-02 Incyte Holdings Corp Bipyratsolijohdannaisia jak-inhibiittoreina
CN105408325B (zh) 2013-07-17 2019-10-22 大塚制药株式会社 氰基三唑化合物
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106413716B (zh) 2014-04-08 2020-03-27 因赛特公司 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
EP2930048A1 (en) 2014-04-10 2015-10-14 Johnson Controls Automotive Electronics SAS Head up display projecting visual information onto a screen
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN107073006A (zh) 2014-09-16 2017-08-18 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂
WO2016064958A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
EP3209664B1 (en) 2014-10-22 2020-06-03 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds as pi3k inhibitors
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
WO2016106624A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
WO2016183062A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
AU2016261730A1 (en) 2015-05-12 2017-11-16 Zeno Royalties & Milestones, LLC Bicyclic compounds
WO2017079519A1 (en) 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
MA54567A (fr) 2016-01-05 2021-10-27 Incyte Corp Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
AU2017316965B2 (en) 2016-08-26 2020-09-10 Mitsubishi Tanabe Pharma Corporation Bicyclic nitrogenated heterocyclic compound
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
DE102017209291A1 (de) 2017-06-01 2018-12-06 Ziehl-Abegg Se Ventilator und Vorleitgitter für einen Ventilator
HRP20240521T1 (hr) 2017-07-24 2024-07-05 Novartis Ag Spojevi i pripravci za liječenje stanja povezanih s aktivnošću nlrp
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
PT3687996T (pt) 2017-09-27 2022-01-21 Incyte Corp Sais de derivados de pirrolotriazina úteis como inibidores de tam
IL301746B2 (en) 2017-10-18 2025-01-01 Epizyme Inc Amine-modified heterocyclic compounds as EHMT2 inhibitors, their salts and a method for their synthesis
US10738057B2 (en) * 2017-10-18 2020-08-11 Incyte Corporation Tertiary alcohols as PI3K-γ inhibitors
JP7194188B2 (ja) 2017-12-19 2022-12-21 ターニング・ポイント・セラピューティクス・インコーポレイテッド 疾患を治療するための大環状化合物
CA3086083A1 (en) 2017-12-21 2019-06-27 Basf Se Pesticidal compounds
KR102746913B1 (ko) 2017-12-21 2024-12-24 베링거 인겔하임 인터내셔날 게엠베하 Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체
WO2020051169A1 (en) 2018-09-05 2020-03-12 Incyte Corporation Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor

Also Published As

Publication number Publication date
PL3847175T3 (pl) 2024-06-17
JP2021535182A (ja) 2021-12-16
AU2019336675A1 (en) 2021-03-25
SG11202102224UA (en) 2021-04-29
TW202024088A (zh) 2020-07-01
HUE066111T2 (hu) 2024-07-28
EP3847175B1 (en) 2024-02-07
HRP20240252T1 (hr) 2024-05-24
ECSP21022719A (es) 2021-06-30
JP7592006B2 (ja) 2024-11-29
CN113677683B (zh) 2025-01-14
MX2021002551A (es) 2021-07-15
MD3847175T2 (ro) 2024-08-31
AU2019336675B2 (en) 2024-09-26
US11186580B2 (en) 2021-11-30
US12173006B2 (en) 2024-12-24
CL2021000539A1 (es) 2021-08-20
MX2023013908A (es) 2023-12-08
IL281262A (en) 2021-04-29
CA3111629A1 (en) 2020-03-12
TWI833796B (zh) 2024-03-01
PH12021550472A1 (en) 2021-11-22
LT3847175T (lt) 2024-03-25
US20200071335A1 (en) 2020-03-05
ES2976576T3 (es) 2024-08-05
CO2021004061A2 (es) 2021-06-10
US20220112198A1 (en) 2022-04-14
RS65334B1 (sr) 2024-04-30
EP4338801A3 (en) 2024-06-05
BR112021004094A2 (pt) 2021-05-25
TW202436300A (zh) 2024-09-16
EP3847175A4 (en) 2022-05-11
PE20211815A1 (es) 2021-09-14
EP4338801A2 (en) 2024-03-20
SI3847175T1 (sl) 2024-05-31
DK3847175T3 (da) 2024-03-18
WO2020051169A1 (en) 2020-03-12
FI3847175T3 (fi) 2024-03-22
MA53561A (fr) 2022-05-11
IL309869A (en) 2024-02-01
CN113677683A (zh) 2021-11-19
KR20210091121A (ko) 2021-07-21
AU2024219757A1 (en) 2024-10-10
PT3847175T (pt) 2024-04-16
CR20210165A (es) 2021-10-01
EP3847175A1 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
IL285686B (en) Crystals in solid form in the presence of an inhibitor
EP3619208C0 (en) CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND
IL287668A (en) Crystalline forms of btk inhibitor
IL289929A (en) Crystal forms of cd73 inhibitor
HUE064943T2 (hu) Szubsztituált tiazolidin vegyület alkalmazása nitrifikációs inhibitorként
IL267393B1 (en) Crystal forms of a Janus kinase inhibitor
IL282454A (en) Crystalline salts of plasma kallikrein inhibitor
IL281262A (en) Crystal forms of phosphoinositide 3-kinase inhibitor (P13K)
SG11202105763SA (en) Novel polymorphic forms of a tgf? inhibitor
IL285020A (en) Topical phosphoinositide 3-kinase inhibitors
LT3891156T (lt) Tienopirimidino, kaip mcl-1 inhibitoriaus, naujos kristalinės formos
IL279953A (en) Crystal forms of LTA4H inhibitor
IL285427A (en) Crystal forms of jak2 inhibitor
DK3947384T3 (da) Isochromen-derivater som phosphoinostid-3-kinase-inhibitorer
SG11202106561RA (en) Crystalline forms of a par4 inhibitor
IL292847A (en) Crystalline forms of magl inhibitor